Multiple myeloma and autologous transplant

Category: Conditions & evidence · Editorial Review: Updated 20 October 2026 · 3 minute read

The purpose of the cells

In multiple myeloma, autologous transplantation commonly supports intensive treatment in suitable patients. Blood-forming cells are collected and preserved before high-dose therapy, then returned to help restore blood production. The antimyeloma treatment and the cell rescue are different parts of the pathway. This should not be confused with a general stem cell infusion marketed for immunity or vitality.

Eligibility and sequence

A myeloma team considers fitness, organ function, disease burden, previous treatment and personal goals. Collection, high-dose treatment and reinfusion occur at different stages. Some plans include treatment after transplant to help maintain disease control. Ask how the proposed sequence fits your prior medicines and whether stem cell collection should occur before additional treatment changes.

Discuss the outcomes that matter

Ask the center to distinguish remission, progression-free time, overall survival and quality of life. A transplant may control disease without guaranteeing that it will never return. When comparing options, ask about the complete treatment program, including maintenance and supportive care, rather than evaluating the reinfusion day as a stand-alone intervention.

International planning

Carry records of bone marrow testing, monoclonal protein results, imaging, kidney function and medications for bone disease. Clarify how stored cells are documented and how collection problems would affect scheduling. Before traveling, establish who will monitor blood counts and myeloma markers after you return home and how urgent complications will be communicated between teams.

Continue exploring

• Acute myeloid leukemia and transplantation
• Acute lymphoblastic leukemia and transplantation
• Non-Hodgkin lymphoma and stem cell transplant
• Prepare your consultation checklist

Sources & further reading

• Primary patient information and research

Read alongside your treating specialist’s advice. Clinical eligibility, exact products and treatment plans require individual assessment.